Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT-787 in Severe Alcohol Associated Hepatitis
NCT05639543Phase 2Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in alcoholic hepatitis (AH) comparing INT-787 with Placebo (2 arms). Primary endpoint: Lille model response based on Lille score at Day 7. Started Dec 2022; status: terminated.
02
Drugs
INT-787
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT05639543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639543.